High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial

Author(s):
Fontein, D.B.Y.; Nortier, J.W.R.; Liefers, G.J.; Putter, H.; Meershoek-Klein Kranenbarg, E.; Bosch, J. van den; Maartense, E.; Rutgers, E.J.T.; Velde, C.J.H. van de (0000-0003-0104-1800)
Published
2012
Publication type
Article / Letter to editor
Non-complianceExtended adjuvant endocrine therapyAdverse eventsEarly stage breast cancerLetrozole
Date issued
2012-02-28
Language
English
Is part of
EJSO (2012), Vol. 38, no. 2, p. 110-117
hdl
1887/96975
doi
10.1016/j.ejso.2011.11.010